Lynn Anne Bristol

Array ( [id] => 19210753 [patent_doc_number] => 11999801 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Multispecific antibodies [patent_app_type] => utility [patent_app_number] => 16/821747 [patent_app_country] => US [patent_app_date] => 2020-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 24 [patent_no_of_words] => 35344 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 484 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16821747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398795 [patent_doc_number] => 20200339653 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => HIGH AFFINITY T CELL RECEPTOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/820856 [patent_app_country] => US [patent_app_date] => 2020-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16820856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16727883 [patent_doc_number] => 20210095030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/820375 [patent_app_country] => US [patent_app_date] => 2020-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16820375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18779124 [patent_doc_number] => 11820818 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-21 [patent_title] => Multi-chain polypeptide-containing tri-specific binding molecules [patent_app_type] => utility [patent_app_number] => 16/818893 [patent_app_country] => US [patent_app_date] => 2020-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 102 [patent_no_of_words] => 44737 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 570 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16468245 [patent_doc_number] => 20200369782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => Monoclonal Antibodies, Compositions and Methods for Detecting Mucin-like Protein (MLP) as a Biomarker for Ovarian and Pancreatic Cancer [patent_app_type] => utility [patent_app_number] => 16/817397 [patent_app_country] => US [patent_app_date] => 2020-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34696 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16817397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16816826 [patent_doc_number] => 11001632 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Anti-CTLA4 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/815560 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 27 [patent_no_of_words] => 18808 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16815560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16816826 [patent_doc_number] => 11001632 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Anti-CTLA4 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/815560 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 27 [patent_no_of_words] => 18808 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16815560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16816826 [patent_doc_number] => 11001632 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Anti-CTLA4 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/815560 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 27 [patent_no_of_words] => 18808 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16815560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16816826 [patent_doc_number] => 11001632 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Anti-CTLA4 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/815560 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 27 [patent_no_of_words] => 18808 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16815560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328448 [patent_doc_number] => 20200299414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => Multivalent Antigen-Binding Proteins [patent_app_type] => utility [patent_app_number] => 16/808775 [patent_app_country] => US [patent_app_date] => 2020-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16808775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18341912 [patent_doc_number] => 11639386 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-02 [patent_title] => Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof [patent_app_type] => utility [patent_app_number] => 16/807514 [patent_app_country] => US [patent_app_date] => 2020-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 62 [patent_no_of_words] => 29576 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16807514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16326876 [patent_doc_number] => 20200297841 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => ANTI-TIM-3 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/806323 [patent_app_country] => US [patent_app_date] => 2020-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50441 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16806323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16634341 [patent_doc_number] => 10912828 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-09 [patent_title] => Anti-TIM-3 antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/806299 [patent_app_country] => US [patent_app_date] => 2020-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 42 [patent_no_of_words] => 50531 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16806299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18492273 [patent_doc_number] => 11697684 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-11 [patent_title] => Tri-specific binding molecules that specifically bind to multiple cancer antigens [patent_app_type] => utility [patent_app_number] => 16/805105 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 28 [patent_no_of_words] => 51115 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 565 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16805105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268875 [patent_doc_number] => 20200270362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => MSLN TARGETING TRISPECIFIC PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/802007 [patent_app_country] => US [patent_app_date] => 2020-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25698 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16802007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15990557 [patent_doc_number] => 20200171149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION [patent_app_type] => utility [patent_app_number] => 16/788488 [patent_app_country] => US [patent_app_date] => 2020-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8442 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16788488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19667571 [patent_doc_number] => 12180299 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use [patent_app_type] => utility [patent_app_number] => 16/738221 [patent_app_country] => US [patent_app_date] => 2020-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 42790 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 343 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16738221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800213 [patent_doc_number] => 20200123249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => METHODS OF TREATING CANCERS USING ANTI-GPRC5D ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/731973 [patent_app_country] => US [patent_app_date] => 2019-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68625 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 259 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16731973 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18153110 [patent_doc_number] => 11566071 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-31 [patent_title] => Nucleic acid molecules encoding anti-GPRC5D antibodies [patent_app_type] => utility [patent_app_number] => 16/732022 [patent_app_country] => US [patent_app_date] => 2019-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 17 [patent_no_of_words] => 68703 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 245 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16732022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328441 [patent_doc_number] => 20200299407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => TRISPECIFIC ANTIBODIES SPECIFIC FOR HER2 AND A BLOOD BRAIN BARRIER RECEPTOR AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/724004 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59817 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16724004 [rel_patent_id] =>[rel_patent_doc_number] =>)